CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA /ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents

Clinical Trial2018 Oct 27. [Epub ahead of print]

JOURNAL:J Am Coll Cardiol. Article Link

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial

M Szarek, HD White, PH Steg, ODYSSEY OUTCOMES Committees and Investigators. Keywords: Alirocumab; acute coronary syndrome; total events

FuLL TEXT PDF